Survodutide (BI 456906)

Published · Researched 2026-09-21

1. Overview

• Maker: Boehringer Ingelheim (with Zealand Pharma as originator/partner). Development code BI 456906.
• Purpose: Dual glucagon receptor (GCGR) / GLP-1 receptor agonist — weekly injectable positioned for obesity and MASH (metabolic dysfunction-associated steatohepatitis). The glucagon component is meant to raise energy expenditure and target liver fat; the GLP-1 component drives appetite suppression.
• Current 2026 version: Investigational — Phase 3 SYNCHRONIZE program. Topline Phase 3 SYNCHRONIZE-1 data announced April 2026; full data presented at ADA 2026 Scientific Sessions. Not approved or marketed anywhere.

2. Social standing

• Platform pulse: Niche but genuinely active in the research-chemical/biohacker peptide scene. Survodutide is the connoisseur's pick among dual agonists — discussed as the "true glucagon analog" alternative to retatrutide, particularly by users who got resting-heart-rate increases on retatrutide.
• Facebook group consensus: No hits in the Facebook groups searched via facebook-cli (Sept 2026) — its community lives on dedicated peptide forums, not Facebook.
• Viral moments: None observed — no viral reels/Threads in 2026.
• Praise: glp1forum users describe it as "very similar to tirz" and a good maintenance/weight-loss candidate; valued for reportedly not raising resting heart rate the way retatrutide does; strong liver-fat reduction data cited as a draw. One user: considering it over retatrutide specifically because "Reta can cause an increase in resting heart rate, where Survo is reported not to have that side effect."
• Complaints: Weaker appetite suppression than tirzepatide/retatrutide is the recurring knock — one glp1forum user "went back to tirz after 1 vial" for that reason; a MESO-Rx user in week 2 reported being "hungry as fuk." A Professional Muscle user who started too high (0.8 mg) reported resting heart rate up 30+ points and feeling "sick like a dog."
• Verified quotes (paraphrased, attributed):
  • glp1forum member: "I only used it for a month. But it felt very similar to tirz in my opinion. I would recommend it as an alternative" — platform: glp1forum.com "Considering Survodutide" thread.
  • glp1forum member: "Tried both serv and maz. Didn't seem to have as good appetite suppression so went back to tirz after 1 vial" — platform: glp1forum.com.
  • thinksteroids (MESO-Rx) member: "2nd week of survodutide (added to my sema+tirz stack). I dont feel the survo at all, I went up to 2mg this week. So far I am just hungry as fuk." — platform: thinksteroids.com.
  • Professional Muscle member M@NU: "survodutide is strong... ive used it for a short time and started slightly too high. my resting heart rate rose over 30 points and i felt sick like a dog." — platform: professionamuscle.com Retatrutide thread.
  • glp1forum vendor-watch posts (Sept 2025): "PGB now has survo back in stock. 12-mg kit for $225 plus shipping... average of three tested vials was 13.07 mg and 99.283% purity"; "Uther has a special right now, I think it's $197 for 10mg"; "TFC Alice has Sur-5 $100 free shipping at $300" — platform: glp1forum.com.

3. Social validation — UNVALIDATED (forum-native, no qualifying Meta-platform signal)

• UNVALIDATED — included for comparison. Its community is forum-native (gray-market peptide boards); no Facebook Groups, Instagram owner content, or Threads owner pulse was found. What follows is the genuine forum evidence, kept because it proves real gray-market self-experimentation and vendor traffic.
• Named sources and what each proves:
  1. glp1forum.com "Considering Survodutide" thread (3 pages, 60+ posts) — proves sustained multi-user discussion: purchase intent, vendor/price sharing, experience reports, stacking debates.
  2. thinksteroids.com (MESO-Rx) "Giant Semaglutide Thread" — proves in-the-wild self-experimentation logs with dosing detail.
  3. professionamuscle.com "Retatrutide" thread — proves bodybuilder-community awareness and adverse-event anecdotes (heart-rate spike).
  4. glp1forum.com "Is any vendor selling Survodutide from China?" thread — proves receptor-affinity comparison culture (Ki binding charts) and vendor sourcing discussion.

4. Key specs table

5. Pricing (dated 2026-09-20)

• Current MSRP (brand): None — investigational, no approved product or price.
• Street price (research chemical, gray-market vendors, community-reported): PGB 12 mg kit $225 + shipping (Sept 2025, glp1forum; Janoshik-tested 13.07 mg avg, 99.283% purity per poster); Uther 10 mg $197 US warehouse (Sept 2025); TFC Alice 5 mg $100 (Sept 2025); earlier promo 100 mg for $170 (~$1.70/mg, ~2024, glp1forum). All prices community-reported, not independently verified — treat as directional.
• Marketplace used range: None observed.

6. What is included / what else is needed

• Brand: N/A (no product).
• Gray-market: Lyophilized powder vial only — requires bacteriostatic water, insulin syringes, alcohol swabs. No pen, no instructions, no quality assurance. Research chemical not for human use.

7. Support reality

• Brand: N/A.
• Gray-market vendors: No warranty/returns in any meaningful sense; community relies on third-party lab tests (e.g., Janoshik) posted by buyers. Vendor reputation is word-of-mouth on forums; several vendor names (PGB, Uther, TFC Alice) appear in Sept 2025 posts with no independent verification of current reliability. Assume no recourse.

8. Community verdict

Survodutide has earned a genuine cult following among dual-agonist experimenters as the "cleaner" retatrutide alternative — prized for liver-fat data and a reputation for less heart-rate elevation. But the honest community read is that its appetite suppression underwhelms next to tirzepatide, and dosing it aggressively produces exactly the heart-rate and nausea problems it was supposed to avoid. Trial data is strong; street verdict is "interesting, not a replacement."

9. Regulatory & safety status

• Investigational drug — NOT FDA/EMA approved. Boehringer Ingelheim's survodutide (BI 456906) is in Phase 3. Any vial sold online is an unapproved research chemical not for human use — never imply otherwise.
• Known safety signals: Trial adverse events predominantly gastrointestinal (nausea, vomiting, diarrhea), concentrated in dose-escalation; 2 treatment-related serious AEs in Phase 2 (3.6 mg group). Community anecdotes: resting heart-rate increases (one report of +30 bpm after overdosing start), nausea, hunger at low doses. Glucagon agonism raises theoretical concerns (glycemic effects, cardiovascular) being watched in Phase 3.

10. Missing-image views + UNVERIFIED points log

• Images found (5/8): hero (vendor vial labeled "Survodutide," multi-mg), detail (Sinopep Pro black-label vial), side (SH-labeled 10 mg "99% purity / for research use only" vial), rear-substitute (Amino Meta 10 mg vial, vendor photo), top-substitute (CertaPeptides vial, vendor photo). All are vendor product photos — no brand product exists. Missing as genuine views: rear, top (both filed with honest substitute labels), owner-in-use, scale, box/accessories.
• UNVERIFIED:
  1. Exact half-life.
  2. Phase 3 maintenance doses.
  3. RESOLVED: the week-count discrepancy is settled — Boehringer Ingelheim's official figure is 16.6% at 76 weeks (efficacy estimand), presented at ADA 2026 and published in NEJM (June 2026). The GMJ outlet's 17.5%/"68 weeks" figure was erroneous and is discarded.
  4. Community receptor-affinity numbers (Ki charts) — user-compiled, not from a citable primary source.
  5. All street prices — community-reported, single time-point (Sept 2025); current Sept 2026 street pricing not confirmed.
  6. Vendor purity claims (e.g., "99.283%") — poster-claimed third-party tests, not independently verified.

Not medical advice. This is research material only; consult a qualified clinician.

Named sources

• glp1forum.com "Considering Survodutide" thread (3 pages, 60+ posts) — proves sustained multi-user discussion: purchase intent, vendor/price sharing, experience reports, stacking debates.
• thinksteroids.com (MESO-Rx) "Giant Semaglutide Thread" — proves in-the-wild self-experimentation logs with dosing detail.
• professionamuscle.com "Retatrutide" thread — proves bodybuilder-community awareness and adverse-event anecdotes (heart-rate spike).
• glp1forum.com "Is any vendor selling Survodutide from China?" thread — proves receptor-affinity comparison culture (Ki binding charts) and vendor sourcing discussion.
• Boehringer Ingelheim — Mechanism: Dual GCGR/GLP-1R agonist; described by community as a "true glucagon analog." Community-cited binding: GLP-1 Ki ~1, GCGR Ki ~8.3 (lower = stronger)
• ADA/diabetes.org Phase 2 summary — Dosing schedule: Weekly subcutaneous injection.
• Trial design — Administration route: Subcutaneous injection (investigational); gray-market lyophilized vials reconstituted with bacteriostatic water
• BI announcement via benefitsandpensionsmonitor.com — Trial phase: Phase 3 (SYNCHRONIZE-1, -2; also MASH program). (Apr 30, 2026)
• healio.com — Measured efficacy: Phase 2 (46 wks): up to 18.7% weight loss at 4.8 mg (ADA 2023). (June 7, 2026)
• Zealand Pharma press release via financialcontent.com — Measured efficacy: Phase 2 (46 wks): up to 18.7% weight loss at 4.8 mg (ADA 2023). (June 7, 2026)
• NEJM / Nature Medicine — Measured efficacy: Phase 2 (46 wks): up to 18.7% weight loss at 4.8 mg (ADA 2023). (June 7, 2026)
• Professional Muscle member M@NU — - Professional Muscle member M@NU: "survodutide is strong...
• Community — | Mechanism | Dual GCGR/GLP-1R agonist; described by community as a "true glucagon analog." Community-cited binding: GLP-1 Ki ~1, GCGR Ki ~8.3 (lower = stronger) | Boehringer…

Source URLs were not recorded for these references.